CSL – UBS rates as Buy

By Broker News | More Articles by Broker News

UBS has re-modelled earnings drivers for CSL and transferred lead analyst coverage. The broker shifts to DCF-based valuation methodology. A three-year compound growth rate for earnings per share of 16% is forecast.

The valuation implies a premium to the company’s historical average relative to the market but UBS believes current plasma industry conditions are favourable. Rating is upgraded to Buy from Neutral. Target is raised to $175 from $155.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $175.00.Current Price is $156.00. Difference: $19.00 – (brackets indicate current price is over target). If CSL meets the UBS target it will return approximately 11% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →